An Ethics Review Argued Denying Patients Medical Marijuana Violates Their Dignity and Rights
After applying the principle of double effect to scientific evidence, an ethics review concluded there was proportionate reason to allow medical marijuana prescribing and that denying effective therapy to seriously ill patients violates their dignity.
Quick Facts
What This Study Found
This ethics review examined the medical marijuana controversy through the lens of biomedical ethics.
The factual foundation was established by the 1999 Institute of Medicine report, in which eleven independent scientists found medical marijuana effective for controlling some pain, alleviating chemotherapy-induced nausea and vomiting, treating AIDS-related wasting, and combating MS-related muscle spasms. The report also found no evidence that marijuana was a "gateway" drug or that medical use would increase illicit use.
Despite this evidence, the DEA refused to reclassify marijuana from Schedule I (no accepted medical use) to Schedule II (medical use with restrictions).
Applying the principle of double effect, a foundational framework in medical ethics for evaluating treatments that have both good and bad effects, the author concluded there was proportionate reason for allowing physicians to prescribe marijuana. The ethical argument was straightforward: seriously ill patients have a right to effective therapies, and denying access denies them dignity and respect.
Key Numbers
Eleven IOM scientists. Four conditions with evidence: pain, chemotherapy nausea, AIDS wasting, MS spasticity. IOM found no evidence of gateway effect.
How They Did This
Ethics review applying the principle of double effect to scientific evidence from the Institute of Medicine report and other sources, examining the tension between drug policy and patient rights.
Why This Research Matters
This was one of the first formal bioethics analyses of medical marijuana policy. By framing the issue as one of patient rights and dignity rather than pharmacology alone, it introduced ethical arguments that proved influential in subsequent policy debates.
The Bigger Picture
The patient rights framework articulated here influenced the medical marijuana advocacy movement and has been cited in legal challenges to cannabis scheduling. The argument that denying effective treatment violates patient dignity became a central claim in medical marijuana policy debates.
What This Study Doesn't Tell Us
The ethical analysis assumed the IOM evidence was definitive, though some of the evidence was preliminary. The principle of double effect, while established in ethics, involves subjective judgments about proportionality. The review did not fully address potential harms of medical marijuana access.
Questions This Raises
- ?Does the ethical framework change as evidence accumulates?
- ?How should regulators balance individual patient rights against population-level harm concerns?
- ?Has the IOM evidence been strengthened or weakened by subsequent research?
Trust & Context
- Key Stat:
- IOM found medical marijuana effective for pain, nausea, wasting, and spasticity with no gateway effect
- Evidence Grade:
- An ethics review grounded in the IOM report. Provides well-reasoned ethical analysis but is ultimately an argument rather than empirical evidence.
- Study Age:
- Published in 2000. The ethical arguments have continued to influence policy as more states and countries have adopted medical cannabis programs.
- Original Title:
- The ethics of medical marijuana: government restrictions vs. medical necessity.
- Published In:
- Journal of public health policy, 21(1), 40-60 (2000)
- Authors:
- Clark, P A
- Database ID:
- RTHC-00090
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is there an ethical argument for medical marijuana?
Yes. This review argued that the principle of double effect supports prescribing marijuana to seriously ill patients and that denying effective therapy violates their dignity and rights.
What did the Institute of Medicine find?
The IOM found medical marijuana effective for pain, chemotherapy nausea, AIDS wasting, and MS spasticity, and found no evidence it was a gateway drug.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-law-and-your-rights-complete-guide
- how-much-weed-legally-possess-state-guide
- crossing-state-lines-with-weed-legal-felony
- medical-card-worth-it-2026-benefits-costs
- how-much-weed-legally-grow-home-state-rules
Cite This Study
https://rethinkthc.com/research/RTHC-00090APA
Clark, P A. (2000). The ethics of medical marijuana: government restrictions vs. medical necessity.. Journal of public health policy, 21(1), 40-60.
MLA
Clark, P A. "The ethics of medical marijuana: government restrictions vs. medical necessity.." Journal of public health policy, 2000.
RethinkTHC
RethinkTHC Research Database. "The ethics of medical marijuana: government restrictions vs...." RTHC-00090. Retrieved from https://rethinkthc.com/research/clark-2000-the-ethics-of-medical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.